AG
MDGL icon

Aperio Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Aperio Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-26
Closed -$3K – 2570
2019
Q2 		$3K Buy
+26
New +$2.79K ﹤0.01% 2892
2015
Q3 		– Sell
-322
Closed -$25K – 1972
2015
Q2 		$25K Buy
+322
New +$27K ﹤0.01% 1996
2014
Q4 		– Sell
-357
Closed -$38K – 1896
2014
Q3 		$38K Buy
357
+19
+6% +$2.64K ﹤0.01% 1725
2014
Q2 		$48K Buy
+338
New +$49.4K ﹤0.01% 1712

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Aperio Group's MDGL Position: Q3 2019 in Review

Aperio Group sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2019, closing a stake of 26 shares — an estimated $3K sold.

Aperio Group first reported a position in MDGL in Q2 2014 and held it in 4 quarters. The position peaked at $48K in Q2 2014. 111 funds tracked by Wall St. Rank hold MDGL as of Q3 2019.

  • Aperio Group reported no remaining Madrigal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 26 Madrigal Pharmaceuticals shares in Q3 2019, an estimated $3K.
  • Aperio Group first reported a position in Madrigal Pharmaceuticals in Q2 2014 and held it in 4 quarters.
  • Aperio Group's Madrigal Pharmaceuticals position peaked at $48K in Q2 2014.
  • 111 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.